S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2
Joel D. A. Tyndall
Abstract
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.
Topics & Concepts
Protease inhibitor (pharmacology)ProteaseCoronavirus disease 2019 (COVID-19)ChemistryPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusVirologyPharmacologyClinical trialDrug discoveryDrugCoronavirus InfectionsComputational biologyEnzymeVirusDiseaseBioinformaticsBiochemistryInfectious disease (medical specialty)Internal medicineViral loadMedicineBiologyAntiretroviral therapyOutbreakComputational Drug Discovery MethodsResearch on Leishmaniasis StudiesSynthesis and biological activity